Acquisition marks fifth laboratory location in the US under DMH see more
Diversified Medical Healthcare (DMH) announces today its acquisition of Meta Lab Dx, marking the 5th laboratory location in the US under the DMH umbrella. DMH laboratories offer thousands of advanced medical diagnostics tests and Meta Lab Dx, located in Charlotte, North Carolina, is serving to expand DMH’s COVID-19 testing portfolio and to uphold the company’s standards of accuracy with 98% of results delivered in under 24 hours.
“When I was first introduced to Diversified Medical Healthcare, I was blown away by all that they’ve accomplished,” said Cody Lay former owner of Meta Lab Dx. “I’m thrilled for Meta to be a part of this company so that we can see Meta Lab Dx reach its full potential and to best serve our customers.”
Diversified Medical Healthcare recently announced a $51,000,000 expansion of its headquarters, adding more jobs and increasing its scale of services provided. It is the holding company for advanced medical diagnostics laboratories Premier Medical Laboratory Services, located in Greenville, South Carolina, First Medical Laboratory Services, located in Irving, Texas, and the American Genetics Institute in Del Ray Beach, Florida. Its other brands, Vessel Medical, CPT Medical, and OnGen operate to conduct medical supply and equipment distribution, sterile medical manufacturing, and medical data management software development.
Founder of Meta Lab Dx, Cody Lay, has now joined DMH as a Strategic Consultant and is overseeing the strategic operations of Meta Lab Dx. He aims to facilitate its continued growth by expanding its services to current clients and utilizing DMH’s national footprint.
“I am more than happy to work alongside Cody in expanding Premier Medical Laboratory Services and Meta itself,” said Kevin Murdock, CEO of DMH. “Acquiring this laboratory will help us to seamlessly expand our laboratory services footprint in the southeast.”
ABOUT DIVERSIFIED MEDICAL HEALTHCARE: Diversified Medical Healthcare (DMH), headquartered in Greenville, SC is a holding entity with several portfolio companies providing healthcare solutions for improved patient care nationwide. Offering advanced clinical laboratory services that span throughout the US, their fully accredited laboratories include Premier Medical Laboratory Services, Dynasty Medical Laboratory Services, First Medical Laboratory Services, Meta Lab Dx ä, and the American Genetics Institute. DMH also provides medical supply and equipment distribution under Vessel Medical, delivers custom procedure trays for various surgical needs with CPT Medical, and helps to quickly and accurately manage medical data with their medical data software company, OnGen. For more information, please visit www.divmedinc.com or call 833.639.0143.
AditxtScore can help physicians determine their patient’s immune status see more
Beginning on Wednesday, August 17, Premier Medical Laboratory Services (PMLS), an advanced medical diagnostics lab, will kick off the first of several webinars throughout the month for healthcare providers covering the benefits of AditxtScoreä for COVID-19 immune monitoring. During the webinar, physicians can learn more about the test and how it can quantify their patients’ individual immune profile. The speaker will discuss how the test provides more clarity regarding a patient’s immune response to the virus and/or vaccine and whether this immune response is likely to provide some protection against future infection.
Whether an individual has been vaccinated or experienced a symptomatic or asymptomatic infection with SARS-CoV-2, AditxtScoreä provides timely information on immune status based on each individual’s unique circumstances. Whether, vaccinated, previously infected or both, AditxtScoreä provides a powerful new tool for physicians to use during the current phase of the pandemic[AV1] . Premier Medical Laboratory Services is hosting these webinars, as they believe this is a test that can effectively help manage future surges in COVID-19 cases by taking subjectivity out of the equation when determining next steps on vaccination, boosting, and precautionary measures. AditxtScoreä helps determine who may be vulnerable to COVID-19.
“We hope these webinars will help equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScoreä, individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action based on high precision data specific to them.”
AditxtScoreä can be used routinely to track changes in immune response over time and contribute greatly to the continued understanding of responses to SARS-CoV-2. The test may help minimize vaccine hesitancy for those who are not protected by antibodies.
To learn more, physicians and healthcare providers can register for the webinar for the following dates at this link: https://bit.ly/3vmgSX4
- August 17th
- August 31st
- September 14th
AditxtScoreä results provide answers to the following questions:
- Does the individual have antibodies present and, if so, are they robust?
- Are the individual’s antibodies present as a result of vaccination and/or viral infection?
- Is the individual’s immune response likely to provide protection against future infection?
*AditxtScoreä has not been authorized by the FDA to evaluate a person’s level of protection from COVID-19 or future SARS-CoV-2 infection. AditxtScore™ is offered through Premier Medical Laboratory Services as an authorized channel partner. Additional terms, conditions and restrictions may apply. Please click on the following link for further information https://premedinc.com/aditxtscore-immune/
Premier Medical Laboratory Services (PMLS), headquartered in Greenville, South Carolina, is the official health and wellness partner of the Greenville Triumph and an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. PMLS prides itself on delivering some of the most rapid turnaround times of testing results in the industry and patient friendly billing. Their expansive menu of highly advanced tests and screenings include genomic risk assessment assays for various cancers, heart disease, and diabetes, as well as women’s health panels, toxicology, allergy testing, pharmacogenomics, routine blood chemistry, and noninvasive prenatal testing (NIPT). With a heartfelt mission to improve patient care, their in-house research and development team of PhD scientists and forward-thinking laboratory staff are continually innovating ways to provide the most highly advanced medical diagnostics available. For more information about PMLS, please visit www.premedinc.com or call 866.312.4707.
About Aditxt, Inc. (“Aditxt")
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com and www.AditxtScore.com.
Expands Prisma Health patient access to laboratory testing see more
In the exchange, Labcorp will acquire select assets of Prisma Health’s outreach lab operations, slated for the second half of 2022, according to a news release.
Labcorp recently partnered with Walmart to distribute at-home COVID-19 tests free of charge.
“Prisma Health is an established leader in providing health care and diagnostic services to South Carolina residents, and its dedication to its patients closely aligns with Labcorp’s mission to improve health and improve lives,” Traci Butler, senior vice president of Labcorp Diagnostics’ Atlantic Division, said in the news release. “This relationship builds on Labcorp’s strong track record of providing the critical information that patients and providers need to make the best possible health decisions. It also underscores our commitment and dedication to the people who call the Carolinas home.”
The new relationship will expand Prisma Health patients’ access to laboratory testing throughout South Carolina and offer individualized, dedicated support to physician practices, modeled after Labcorp’s partnerships with other health care systems, according to the release.
“Labcorp brings the scale and expertise of its internationally recognized laboratory services to help us achieve the next level of service and quality in this highly specialized area,” Clarence Sevillian, executive vice president and chief operating officer of Prisma Health, said in the release. “We pride ourselves on providing the best possible experiences for our patients and providers. This relationship is another way we are building on our strong reputation of quality care and compassionate service, helping people in communities across South Carolina live their healthiest lives.”
Once the transactions are complete, Prisma Health patients and clinicians will have access to a spectrum of services through Labcorp’s lab test menu, along with its national network of patient service centers.
Labcorp will also offer expanded health plan coverage, additional access to rural markets and the potential for reduced out-of-pocket lab costs for patients, according to the release. Additionally, Labcorp will collaborate with Prisma Health to provide same-day STAT testing in local communities.
Specific terms of the transactions were not disclosed.
FDA Grants Emergency Use Authorization to Premier Medical Laboratory Services for At-home COVID-19 TestAssay designed for RapidRona at home tests see more
Premier Medical Laboratory Services (PMLS), one of the largest private medical diagnostics laboratories in the US has provided results for millions of COVID-19 tests since the beginning of the pandemic, contributing largely to the national COVID-19 response. They have also implemented one of the largest variant surveillance initiatives in the country with the capability to sequence up to 42,000 specimens per day. Now, they have been granted Emergency Use Authorization (EUA) from the Food and Drug Administration to process results for at-home COVID-19 tests.
The RT-PCR-based SARS-CoV-2 assay now authorized by the FDA is designed for RapidRona at home tests which can be ordered online at www.rapidrona.com. RapidRona enables those who would like to test for COVID-19 to collect their own sample at home by a minimally invasive nares swab and then send the specimen with prepaid shipping to the lab for processing of results. Polymerase Chain Reaction (PCR) tests have been known throughout the pandemic as the gold standard of testing methods due to the highly accurate results that they provide.
“Our scientists have worked diligently to take the steps necessary in receiving the EUA for this test,” said Kevin Murdock, Founder and CEO of Premier Medical Laboratory Services. “We did this because we know how important it is to enable the population to more easily access reliable COVID-19 tests with fast turnaround times from home. We’re proud that this is another way we can provide effective solutions for COVID-19 management.”
At-home COVID-19 tests have been reported as difficult to find during the Omicron surge. The EUA attained by PMLS will allow more people the ability to test and mitigate the spread of the virus. Because some countries around the world only accept incoming travelers who have taken a RT-PCR test with a negative result, RapidRona is the choice for at-home testing among travelers. Returning schools and businesses can also reduce viral transmission rates utilizing RapidRona’s sample collection method designed for improved comfortability, keeping infected employees, students, and staff to a minimum.
PMLS is part of a house of brands under Diversified Medical Healthcare which manufacture testing supplies, develops medical data management software, and provides PPE to seamlessly meet the needs of organizations without delay or disruption.
During the pandemic, PMLS has:
- Processed millions of COVID-19 tests with a turnaround time of 24 hours or less
- Served as the choice processing lab for Health and Human Services testing sites
- Been the trusted COVID-19 management partner for professional sports teams, schools, colleges, large corporations, and health departments spanning from coast to coast
ABOUT PREMIER MEDICAL LABORATORY SERVICES: Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS), easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry and patient-friendly billing. Their expansive testing menu includes advanced Cardiovascular Testing, Diabetes panels, Pharmacogenomics, COVID-19 testing, Women’s Wellness panels, Allergen Specific Ige Blood Testing, and Toxicology. For more information, please visit www.PreMedInc.com or call 1.866.800.5470.
Life sciences firm seeking to add hundreds of new employees see more
Premier Medical Laboratory Services, has recently reported a rapid increase in medical testing demands coming to their laboratory – the amount of COVID-19 tests alone being processed at their Greenville, SC facility has jumped 250% in the last two weeks. Much of this is due to the Omicron variant, which first made landfall in the US at the beginning of December and is now the dominant strain of the virus in the nation. With this influx of tests poses an immediate need for hundreds of Upstate employees to be hired at the medical laboratory.
“Throughout the pandemic we’ve been proactive in fulfilling our staffing needs,” said Kevin Murdock, CEO and Founder of Premier Medical Laboratory Services. “To ensure that we continue to properly meet testing demands amid this new surge, we are looking to vastly expand our team and to provide jobs in the community.”
PMLS is a CLIA and COLA certified laboratory. They are the choice processing lab for Health and Human Services testing sites, and the trusted COVID-19 management partner for professional sports teams, schools, colleges, large corporations, and health departments across the nation. With an expanding team, they are inviting members of the Upstate community to join them in providing vital services and information, helping to battle COVID-19 and its new variants and to improve the future of healthcare with advanced medical diagnostics. Currently, the lab is looking to fill the following positions:
Lab Data Entry Clerk
- NO EXPERIENCE NEEDED
- Job duties include entering patient information into a computer system, scanning barcodes, and helping with any other lab assistant needs
- Protective gear and all training are provided by the lab
Job Type: Part-Time; Pay: $15 per hour
Medical Laboratory Technician
Responsible for performing medical tests in the Molecular Lab. Does not need to be certified if a degree in Chemistry or Biology have been attained.
- Collect and organize blood, tissue, and other bodily fluid samples from patients
- Prepare samples for routine testing and analysis
- Properly record results for further analysis and easy reference
- Monitor inventory samples and supplies
- Maintain a clean work environment
- You must have experience as a Medical Technologist (ASCP Certificate that is CURRENT is a plus!)
- BS in Biology or Chemistry is also helpful
- Familiarity with common medical terminology
- Experience in a laboratory setting
- Strong organizational skills
Job Type: Full-time; Pay: $18-$22 per hour
- ***MUST HAVE EXPERIENCE WITH MANUAL EXTRACTION PROCESSES***
- Has earned a bachelor's degree in a chemical, physical or biological science or medical technology from an accredited institution
- Has at least 2 years of current laboratory experience, in moderate complexity testing (Chemistry, Hematology, Urinalysis)
- Has 2 years of laboratory training or experience in high complexity testing (Allergy and/or Molecular)
Job Type: Full-time; Pay: $24-$28/hr
All positions located in Greenville, SC. Please email: HR@DIVMEDINC.COM to apply. For more information, please visit www.PreMedInc.com or call 1.866.800.5470.
ABOUT PREMIER MEDICAL LABORATORY SERVICES
Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women's Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DIABETESPredict. For more information, please visit www.PreMedInc.com.
Nephron Pharmaceuticals continues on rapid growth curve... see more
Nephron Pharmaceuticals’ expansion is progressing as production gets underway on a spate of new business ventures — from at-home COVID-19 test kits to chemotherapy drugs.
Since 2020, the West Columbia drug maker has invested $215 million to build out its campus in Lexington County’s Saxe Gotha Industrial Park. In the past month, the company hired 1,500 new part-time workers as it ramps up production of new product lines, CEO Lou Kennedy said, bringing it to 1,200 full-time employees and 2,500 part-timers.
The hiring spree comes as Nephron produced 30 million doses of reagent for Abbott Laboratories’ at-home COVID-19 test kits last month and assembled about 1 million kits. Kennedy hopes to increase kit production to 2 million per month in January as demand for them has skyrocketed amid new variants of the deadly virus.
Premier Medical Laboratory Services, in Partnership with the Clemson University, Reports Omicron Variant Now Present in Upstate, SCPremier Medical, Clemson detect latest variant in Upstate region see more
December 20, 2021 – Today, Premier Medical Laboratory Services (PMLS), headquartered in Greenville, SC, reports their findings that the Omicron variant is now confirmed to be present in the Upstate. The laboratory has been surveilling for Omicron and other novel variants through Next Generation Sequencing (NGS) in partnership with the Clemson University Bioengineering Department. Clemson University REDDI Lab has collected samples for COVID-19 testing from throughout the upstate community and was funded through the National Institutes of Health (NIH) to then have the COVID-19 positive specimens undergo NGS at PMLS. NGS is the process of decoding the genetic make-up of the virus to track how it is mutating and spreading throughout the population.
“As a proactive and solutions-driven company, we implemented Next Generation Sequencing to meet the needs of our population with preparedness for novel variants like Omicron,” said Kevin Murdock, CEO and Founder of Premier Medical Laboratory Services. “Through partnerships like ours with Clemson University, we are happy to increase the amount of data for South Carolina and the entire nation which is vital for vaccine efficacy and our understanding of the virus.”
Knowing the importance of accumulating data in the continued fight against the pandemic, PMLS implemented one of the largest sequencing initiatives among any lab in the nation – with the capability to sequence up to 42,000 samples per week. Many labs that are conducting COVID-19 testing have not developed the capabilities to conduct sequencing, and new variants cannot be fully identified via COVID-19 diagnostic testing methods alone. PMLS will continue working to uncover any further novel variants and mutations that COVID-19 presents and notify health officials.
Other ways PMLS has helped to meet demands during the pandemic:
- Processing lab for Human Health Services surge sites and several state health departments
- Blue Cross Blue Shield preferred COVID-19 testing lab in several states
- Reached one of the highest testing capacities in the nation with the capability to process over 300,000 tests per day
- Developed medical data management software that communicates directly from laboratory equipment for faster HIPAA compliant delivery of data to healthcare providers and patients
- Shifted production to add in-house manufacturing of COVID-19 testing kits
- Donated thousands of COVID-19 tests to children's diabetes summer camps throughout the nation
- Donated hundreds of thousands of masks to local law enforcement, paramedics, fire departments, hospitals, and the Shriners organization and has provided free testing to first responders during the pandemic
For more information, please visit www.premedinc.com or call 1.866.800.5470.
ABOUT PREMIER MEDICAL LABORATORY SERVICES
Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women's Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and highly advanced diabetes test, MDDiabeticPro. For more information, please visit www.PreMedInc.com
GSSM Honors Dr. Delphine Dean of Clemson University with 2021 Randall M. La Cross Distinguished Research Leadership AwardDr. Delphine Dean of Clemson honored see more
The Governor’s School for Science + Mathematics (GSSM) was pleased to award the Fall 2021 Randall M. La Cross Distinguished Leadership Award to Dr. Delphine Dean of Clemson University at the 33rd Annual Research Colloquium.
Dr. Delphine Dean is the Rob and Jane Lindsay Family Innovation Professor of Bioengineering at Clemson University. Dr. Dean earned her B.S., M.Eng., and Ph.D. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology. She joined the Clemson University faculty in 2007. She is a member of the American Chemical Society, American Physical Society, Materials Research Society, Biomedical Engineering Society, Society for Biomaterials, American Society for Engineering Education, the Orthopaedics Research Society, and is one of the newest members of the American Institute for Medical and Biological Engineering’s College of Fellows. Dr. Dean is a recipient of the Class of ’39 Award for Excellence from Clemson University.
Dr. Dean’s Multiscale Bioelectromechanics Lab at Clemson University studies the mechanics and interactions of biological systems at the nano-to micro-scale using techniques like atomic force microscopy and mathematical modeling. Her research focus includes the nanostructure of cardiovascular cells and tissues, the effects of ionizing radiation, and the development of novel medical devices. These innovations include saliva-based blood glucose strips that can be read by a smartphone application and a biodegradable marker for tumor localization that reduces the cost of breast cancer surgery.
Many of the projects led by Dr. Dean address needs in under-resourced communities around the world – a commitment aligned with that of GSSM’s mission to develop “ethical leaders” prepared to take on “the world’s most significant issues.” These efforts include a breast pump with a filter to inactivate HIV in breast milk, basket-woven braces for neck injuries that can be produced and sold by local women in Tanzania, and a low-cost patient monitor that a hand crank can power.
In response to the COVID-19 pandemic, Dr. Dean led the establishment of the certified clinical diagnostic Research and Education in Disease Diagnosis and Intervention lab at Clemson, which is key to Clemson’s COVID-19 testing strategy, as well as providing testing for their surrounding community. She also led the Clemson COVID Challenge, an undergraduate research, and design challenge to address issues related to the pandemic.
A core element of Dr. Dean’s work has been to engage students below the graduate school level with challenging and meaningful projects. Dr. Dean has provided mentored research & inquiry experience to over a dozen GSSM students since 2008 and over 150 Clemson undergraduates through Clemson’s Creative Inquiry program. Current student projects include designing medical devices for the developing world, collaborating on biomedical engineering innovation with students in Tanzania, testing radiation for biomedical applications, using magnetic nanoparticles to reduce the need for arterial stent implants, and applying human factors engineering to medical device design.
The Randall M. La Cross Distinguished Research Leadership Award is presented to Dr. Dean by Dr. Tyler Harvey. Dr. Harvey is a GSSM Class of 2011 graduate. As a rising senior at GSSM, he conducted his mentored research & inquiry experience at Clemson University under Dr. Dean. He returned to Clemson, earning his B.S., M.S., and Ph.D. while continuing research with Dr. Dean. Dr. Harvey is currently a Lecturer in Bioengineering at Clemson University and has contributed to the development of GSSM Outreach & STEM Foundations programs.
Vigilent Labs Relocates to New Charleston, SC Facility to Meet Demand for COVID-19 Test Kits see more
RYSE Asset Management, a United Kingdom-based global financial investment firm, has listed Vigilent Labs as an investment opportunity. RYE Asset Management invests in early-stage health data technology firms that demonstrate promising growth on a global scale. RYSE connects high-potential healthcare firms with established global distribution partners.
The announcement came as Vigilent Labs announced the relocation of its Headquarters from the Charleston Navy Yard to 3860 Faber Place Drive, North Charleston. The 10,000 square feet of office and light manufacturing space will serve as its headquarters and East Coast manufacturing operations site to streamline with its international partners, SeroClinix and UniBiosciences (UBS), and meet the increasing demand for COVID-19 Antigen and Antibody test kits worldwide. Vigilent Labs is an advanced health and medical technology company providing solutions for the detection and identification of health and bio threats and diseases.
Established in 2019, the company has an internationally renowned team of medical scientists, healthcare physicians, and business executives. The company offers FDA/EUA approved COVID-19 (and its variants) test kits, Influenza A, Influenza B, and Norovirus, and more.
Vigilent Labs’ technology is unique, because test results can be loaded onto their proprietary v. Labs Platform© (VLMS), and leverage its v. Resolute Reader, lab in your hand that provides rapid and accurate screening results.
John Falk, Founder & President of Vigilent Labs said, “We are beyond thrilled to have been listed by the prominent financial firm RYSE Asset Management; while, at the same time, our Leadership Team and Board has made the strategic decision to locate closer to the Charleston Airport opening other logistical channels for the current and future production and distribution of our test kits and devices throughout the United States and around the globe.”
To learn more information: www.vigilentlabs.com
To learn more information: www.ryseam.com
PMLS picks new Chief Commercial Officer for fast-growing organization see more
Premier Medical Laboratory Services (PMLS) is announcing today Jeff Schmalz as their new Chief Commercial Officer. At PMLS, Jeff will be focusing on the major disciplines impacting lab growth including partnerships, product development, clinical outreach, sales infrastructure, customer service and marketing. With 35 years of experience in multiple healthcare organizations, he brings extensive knowledge in the diagnostics and reference lab markets.
In his latest role, he led the segment marketing and business development team responsible for integrating specialty labs, technology, and test launches that contributed to several hundred million in additional revenue growth. Jeff also oversaw the launching, branding, and commercializing of Lab Developed Tests (LTDS) over a period of 15 years for 25 test classes resulting in over $400M per year in revenue. He has founded, developed, and launched international partnerships to carry out his sales initiatives and maximize overall market share.
“I chose to work at Premier Medical Laboratory Services because they’re an innovative and nimble company with all of the components in place to make them a national leading specialty lab,” said Jeff Schmalz. “They lead with a forward-thinking approach to unmet needs within the healthcare industry and continually build on their capabilities to bring the most advanced medical diagnostics services for better patient outcomes…and that’s something I want to be a part of and advance forward.”
As a graduate and scholarship athlete from the University of Maryland, Jeff pursued an executive management MBA curriculum from the Kellogg School of Management. Since then, he has served as a board member for the Biomedical Marketing Association and successfully launched products at Abbot, Chiron, LabCorp, Digene, Bayer and Qiagen. He managed a team of 53 segment leaders, product managers, and marketing communication strategists by positive motivation, leading by example, and empowering them to make decisions and take initiative.
“We are at an integral phase in our growth here at Premier Medical Laboratory Services as a top lab with the mission to bring the most advanced diagnostics to our nation,” said Kevin Murdock, CEO and Founder of PMLS. “The level of talent and experience that Jeff Schmalz possesses will help us tremendously in fulfilling our vision of improving patient lives.”
ABOUT PREMIER MEDICAL LABORATORY SERVICES
Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women's Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DIABETESPredict. For more information, please visit www.PreMedInc.com
University of South Carolina initiative saving lives see more
A gentle hum can be heard from a lab in the depths of the University of South Carolina's life sciences building. Take a peek inside, and you'll find something unusual.
Thousands of tubes of the spit belonging to the university's students, faculty, staff and Columbia residents.
Almost a year ago, the school's colon cancer lab changed course from its usual area of study and started analyzing how it could help as COVID-19 ravaged the world, killing hundreds of thousands across the country and shutting down campuses.
USC professors had a breakthrough when they started studying saliva there, said biomedical sciences professor Phillip Buckhaults.
They ended up creating what looks like a blue cocktail — and it exposes the COVID-19 genome in our saliva.
"We figured out a way to photocopy bits of the COVID genome," Buckhaults said. "It's like a liquid photocopier."
It's proven to be more efficient than nasal swabs for COVID-19 testing. There's no uncomfortable nasal swab involved. Materials for nasal-swab testing are often limited. And these saliva results come quicker. Those who get tested on USC's campus typically receive results within 24 hours.
When the saliva testing first began on campus, scientists were pipetting saliva samples with the "photocopier" liquid to see the COVID-19 genome appeared in the DNA when the saliva was "photocopied" several times.
Because it was done solely by hand, they were able to test only several dozen samples a day.
"The demand was more than we could keep up with," Buckhaults said.
So he sent an email pleading with USC president Harris Pastides for a liquid-handling robot that's able to do the pipetting automatically, saving a lot of time.
Pastides then got South Carolina-based Nephron Pharmaceuticals owner Lou Kennedy to write Buckhault a $14,000 check to buy one of the robots.
"Within two weeks, we went from a junkie, underutilized, decrepit lab space to really state-of-the-art," said laboratory director and professor Carolyn Banister.
Buckhaults also credited former USC president Bob Caslen for removing roadblocks to get more machines and a bigger lab — speeding up the process to speed up the process, so to speak.
Caslen worked with the state government and university officials to get thousands of dollars for lab equipment and borrowed testing machines from nearby labs, Buckhaults said.
"He saved a lot of lives in the Midlands by pouring resources into (Banister) and that lab and getting this test running," Buckhaults said.
Now, the lab is testing about 2,000 samples a day and returning samples within 24 hours, and its reach is beyond the Midlands. Quick-turnaround testing allows people to identify themselves as COVID-19-positive earlier and isolate themselves, reducing the spread of the virus and saving lives.
The testing technology has expanded across the state. USC satellite campuses, including Upstate and Union, as well as Clemson, Winthrop, the College of Charleston and Trident Technical College are able to use the saliva tests created at the USC lab.
The testing is able to recognize different variants of COVID-19 as well.
PMLS donates rapid antigen tests to Diabetes Education camps see more
Premier Medical Laboratory Services donates rapid antigen tests to Diabetes Education and Camping Association Camps
Many children with diabetes look forward to summer camp each year to, not only spend time with friends, but with other children who can relate to similar day-to-day obstacles that living with diabetes can present. The Diabetes Education and Camping Association (DECA) unites the global diabetes camping community, providing leadership, education, and resources to make camps for those with diabetes more impactful. As most summer camps across the US resumed this year, diabetes camps were faced with the extraordinary obstacle of protecting children who are at higher risk for COVID-19 complications due to diabetes. To bring summer camps for children living with diabetes back this year and to help protect these children, one of the nation’s largest laboratories, Premier Medical Laboratory Services, donated thousands of COVID-19 tests to DECA camps in 19 states across the nation, enabling them to safely return to camp this year.
“We know DECA and each of their camps do so much for the diabetes community - helping kids to learn how to manage the disease as well as support emotional wellbeing,” said Kevin Murdock, Founder and CEO of PMLS. “With diabetes being a global pandemic, it’s a large focus for Premier Medical Laboratory Services to provide top healthcare solutions for patients with diabetes. We are honored to help camps that improve the lives of children and adolescents with diabetes.”
For some children, a diabetes camp is their first opportunity to meet a friend who also has diabetes, or their first time staying somewhere without their parents. It’s a great place for them to adopt a new hobby or learn skills that give them more self-confidence. Along with the feeling of independence and support, diabetes camps have been shown to provide children with an increase in diabetes self-care abilities and decreased diabetes-specific distress. (1) For caregivers, diabetes camps provide a medically sound environment where they can feel assured that their children are safe and their diabetes care needs are met.
Terry Ackley, Executive Director of DECA added: “The safety of children with diabetes is the highest priority of diabetes camps. Covid-19 has presented significant challenges to the operation of diabetes camps this year. It has required that they carefully study their program delivery model and incorporate additional health and safety protocols following the newest guidelines from the Centers for Disease Control. A tool that is very important to safely serving children with diabetes at camp is Covid-19 testing. Premier Medical Laboratory Services approached the diabetes camping community to offer their much-needed support. Our community greatly appreciates their generous donation of a large quantity of rapid antigen tests to diabetes camps across the United States. Premier Medical Laboratory Services has been instrumental to the ability of diabetes camps to operate this year. Their support is helping children learn more about how to manage their diabetes, build resilience to living with this difficult health condition, develop cherished friendships and have lots of fun!”
Aside from offering COVID-19 testing and many other medical diagnostics solutions, PMLS is continually searching for innovative diabetes prevention and maintenance applications. With some of the most advanced testing panels for both type 1 and type 2 diabetes, PMLS also introduced to the US a first of its kind predictive genetic test for type 2 diabetes, which allows patients to know their risk of future onset of the disease determined by their individual genetic make-up. Along with this, Premier Medical Laboratory Services is currently working with the Juvenile Diabetes Research Foundation on initiatives to bring soccer clinics to diabetes communities as part of their mission to improve patient lives both medically and through community outreach. PMLS is soon to announce more breakthrough solutions for diabetes care.
For more information on Premier Medical Laboratory Services, please visit www.premedinc.com or call 866-387-2909.
Test results are delivered straight to the customer in 48 hours or less see more
Diversified Medical Healthcare, a conglomerate of four Greenville health care companies specializing in advanced molecular diagnostics, medical supplies and laboratory equipment, recently acquired the COVID-19 home testing company, RapidRona.
RapidRona test results are delivered straight to the customer in 48 hours or less, according to a news release.
“We know that COVID-19, unfortunately, is something our population will continue to face,” Kevin Murdock, CEO and founder of Diversified Medical Healthcare, said in the news release. “As recent reports show that the new variants spread faster, cause more severe symptoms, and are causing a decrease in vaccine efficacy, the acquisition of RapidRona is our logical next step in providing necessary solutions for the future of COVID-19. We’re proud to add at-home diagnostic and wellness testing to all that we offer at Diversified Medical Healthcare.”
According to a recent Yale Medicine article cited by the release, the Delta variant is spreading 50% faster than the Alpha variant, which was 50% more contagious than the original strain of COVID-19.
According to data cited by the press release, “1,271 of 1,528 total new infections were fully vaccinated individuals as were 23 of 27 hospitalizations and 11 out of 17 cases of severe illness.”
Pivoting from a trend of at-home COVID-19 antigen tests, RapidRona kits provide RT-PCR tests.
“We are excited to see the technology platform in good hands advancing the consumer’s ability to proactively direct their health care from home,” Former RapidRona CEO Heather Mlodinow said in the release.
Diversified Medical Healthcare has reached one of the highest testing capacities in the nation with the capability to process more than 300,000 tests per day, according to the release. They’ve also shifted production to add in-house manufacturing of COVID-19 testing kits and reagents to combat infrastructure limitations and make testing more accessible.
Nation-Leading COVID-19 Variant Surveillance Initiative Now Underway: Premier Medical Laboratory ServicesPMLS launches one of the nation’s largest variant surveillance initiatives see more
The Biden Administration announced Friday a $1.7 billion investment to monitor new and emerging COVID-19 variants which could induce another pandemic wave. Concurrently, to combat these mutated strains, advanced molecular diagnostics laboratory, Premier Medical Laboratory Services announces their launch of one of the nation’s largest variant surveillance initiatives. Now conducting genomic sequencing of 6,000 specimens per day, PMLS plans to increase that number to 12,000 by May. The large amounts of data gathered by this initiative will help protect the population from a future surge and cases with increased severity of symptoms.
When speaking on Pfizer’s ability to adjust the vaccine for effective inoculation against the new variants, a Pfizer Executive said Saturday, “You can basically, within a couple of weeks, put a new sequence in.” In order to make these adjustments to vaccines, scientists developing them need genomic sequencing data on a large scale, like that being produced by PMLS.
Scientific Director of Clinical Genetics for PMLS, Vidhya Narayanan commented, “Sequening information and population studies can give us vital information regarding evolution of the COVID 19 virus and transmission pattern which otherwise can go unnoticed.”
The COVID-19 virus is structured so that inside each nucleocapsid protein is the viral genome, which over time can mutate for the virus to be more efficient at spreading and to potentially cause more severe illness than the original strain. Genomic sequencing decodes the genomes to learn about the virus and how it is evolving. Standard polymerase chain reaction (PCR) COVID-19 tests, which are most widely used for detection of the COVID-19 virus, are very specific to detecting the pathogens of the original COVID-19 strain. Next generation sequencing is able to detect new pathogens so that epidemiologists can study viral genome mutations to understand how they affect the viral characteristics of COVID-19 and to determine future health implications the novel variants may cause.
Because library prep instruments and genomic sequencers are in short supply, many laboratories spend hours conducting library prep and sequencing manually. With high throughput genomic sequencers and library prep instruments that automate the library prep and sequencing process, PMLS achieves a much higher capacity for genomic sequencing. By monitoring an exponentially higher amount of specimens, PMLS is better equipped to provide meaningful analysis with larger amounts of data and faster turnaround times for the effective surveillance of SARS-CoV-2.
“We want to be proactive with these new variants in case any adjustments need to be made within the healthcare industry for patient care or new safety protocols need to be put into place,” said Kevin Murdock, Founder of Premier Medical Laboratory Services. “Data is the most vital piece in beating this pandemic, so we made this a top priority to aquire the most advanced sequencing equipment and top scientists to help monitor them.”
Of growing concern, among other variants, is the Indian variant (B.1.617), which has spread to the UK and made landfall in California approximately two weeks ago. This variant is potentially the catalyst for a recent surge of cases in India and is believed to have more rapid rates of transmission than the original strain like the UK variant (B.1.1.7) that is estimated 50 percent more than the standard form of SARS-CoV-2 which is also been shown to cause higher mortality rates. (1,2)
Other current known variants:
- Brazil (P.1)
- South Africa (B.1.351)
- California (B.1.427/B.1.429)
- New York (B.1.526)
The high-volume sequencing being conducted at PMLS follows suit with COVID-19 testing solutions they have provided as a laboratory with one of the highest testing capacities in the nation. Their ability to test over 300,000 specimens per day for COVID-19 paired with their rapid turnaround of accurate results is why they are the chosen laboratory to conduct testing for Human Health Services surge sites, large organizations, schools, athletic teams, and state health departments across the US.
According to the CDC, genomic surveillance can help detect variants with:
- Ability to spread more quickly in people
- Ability to cause either milder or more severe disease in people
- Ability to evade detection by specific diagnostic tests
- Decreased susceptibility to therapeutics that employ monoclonal antibodies
- Ability to evade natural or vaccine-induced immunity (3)
- Harvard Magazine https://harvardmagazine.com/2021/01/covid-19-variants
- Nature Research Journal: https://www.nature.com/articles/s41586-021-03426-1
- CDC: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance.html?CDC_l.html
For more information, please visit www.premedinc.com/ngs or call 1.866.800.5470.
ABOUT PREMIER MEDICAL LABORATORY SERVICES
Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women’s Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DiabetestPredict. For more information, please visit www.PreMedInc.com
Vigilent Labs to distribute COVID-19 test kits and digital health credentials see more
Enables Vigilent Labs to distribute COVID-19 test kits and digital health credentials to government organizations through GSA schedule
Vigilent Labs, an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats, has formed a partnership with Seroclinix and Davenport Aviation to distribute COVID-19 test kits and Vigilent Labs v.Pass digital credential technology through Davenport Aviation’s General Services Administration (GSA) Contract.
“Our government division has worked on adding much-needed medical supplies to our GSA contract to meet our nation’s most pressing needs during the COVID-19 pandemic,” said Rob McMillin, Davenport’s Senior Program Manager. “We are pleased to partner with Vigilent Labs and Seroclinix to provide test kits to government customers through our GSA Contract (#GS-07F-139DA).”
The COVID-19 Rapid Test kit partnership with SeroClinix’s cost-effective SIENNA Antibody Tests produces fast, reliable and accurate results in seven to 10 minutes, which are CE-marked useful for COVID-19 screening and surveillance under CDC guidance, recently received high marks fro3m the latest International Journal of Infectious Diseases evaluation, and now authorized and approved for purchase through GSA Advantage. A critical advantage of this partnership is the Vigilent Labs “v.LABS” platform and its ability to convert the SIENNA test results into a digital credential that includes one’s COVID-19 Test Results in a v.PASS, facilitating near-real-time health surveillance.
“Vigilent Labs leverages our existing capability with leading-edge technology to provide a comprehensive solution to the medical community from the Point Of Care environment to the executives and managers responsible for healthcare decision making,” said John Falk, President of Vigilent Labs. “We are proud of this strategic partnership and to provide quality testing and credential solutions to government organizations.”
This partnership marks an important milestone for Vigilent Labs as an authorized GSA/Government reseller and distributor for COVID-19 Antigen and Antibody test kits in the United States for the United States government.
“We are excited for our partnership with Vigilent Labs in providing fast and effective test kits for the government,” said Howard Lee, Chief Executive Officer of Seroclinix. “These tests are not only cost-effective but also have the highest reviews made by independent medical evaluations as to the accuracy of the test.”
To learn more about Vigilent Labs’ solutions for COVID-19 testing and monitoring, visit www.vigilentlabs.com.
About Vigilent Labs
Vigilent Labs is an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats. The company provides point-of-care (POC) medical testing devices, initially centered on the COVID-19 pandemic, paired with a comprehensive digital health and credentialing platform that offers near real-time tracking of disease. Founded in 2019, Vigilent Labs is headquartered in Charleston, South Carolina, with additional manufacturing and production facilities in Laramie, Wyoming and throughout the United States. For more information, visit www.vigilentlabs.com.